🇺🇸 FDA
Pipeline program

REGN5381

R5381-HF-22118

Phase 2 small_molecule terminated

Quick answer

REGN5381 for Heart Failure is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Heart Failure
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials